These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 9147914)

  • 1. Quality control guidelines for amoxicillin, amoxicillin-clavulanate, azithromycin, piperacillin-tazobactam, roxithromycin, ticarcillin, ticarcillin-clavulanate, trovafloxacin (CP 99,219), U-100592, and U-100766 for various National Committee for Clinical Laboratory Standards susceptibility testing methods. Results from multicenter trials.
    Worth S; Erwin ME; Jones RN
    Diagn Microbiol Infect Dis; 1996 Feb; 24(2):87-91. PubMed ID: 9147914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of bovine lactoferrin on the MICs of ampicillin/sulbactam (UNASYN), amoxicillin/clavulanic acid (Augmentin), ticarcillin clavulanate (Timentin), and piperacillin-tazobactam (ZOSYN), against clinical and environmental isolates of motile Aeromonas.
    WaKabongo M; Stucki ZN; Torbert DP; Olweny J
    J Am Osteopath Assoc; 2005 Jan; 105(1):25-6. PubMed ID: 15710671
    [No Abstract]   [Full Text] [Related]  

  • 3. [Bactericidal activity of combinations of ticarcillin-clavulanic acid or other beta-lactams (amoxicillin, piperacillin-tazobactam, ticarcillin) with gentamicin against Enterococcus faecalis and E. faecium].
    Leclercq R; Duval J
    Pathol Biol (Paris); 1995 Apr; 43(4):245-52. PubMed ID: 7567109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proposed interpretive criteria and quality control parameters for testing susceptibility of Neisseria gonorrhoeae to beta-lactam-clavulanate combinations.
    Fuchs PC; Barry AL; Baker CN; Murray PR; Washington JA
    J Clin Microbiol; 1992 Aug; 30(8):2191-4. PubMed ID: 1500533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of piperacillin-tazobactam susceptibility among Enterobacteriaceae, Pseudomonas aeruginosa, and other bacteria using ticarcillin-clavulanic acid, ceftazidime, and other broad-spectrum antimicrobial in vitro test results.
    Jones RN; Sutton LD; Cantrell HF; Lankford RB
    Diagn Microbiol Infect Dis; 1994 Nov; 20(3):143-9. PubMed ID: 7874881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Piperacillin tazobactam compared with co-amoxiclav, ampicillin plus sulbactam and timentin against beta-lactamase-producing clinical isolates of Escherichia coli, Klebsiella pneumoniae and Klebsiella oxytoca.
    Traub WH; Leonhard B
    Chemotherapy; 1995; 41(5):345-52. PubMed ID: 8521736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Piperacillin/tazobactam compared with ticarcillin/clavulanate in community-acquired bacterial lower respiratory tract infection.
    Shlaes DM; Baughman R; Boylen CT; Chan JC; Charan NB; Cormier YC; Erickson A; Grossman R; Kirmani N; Suh B
    J Antimicrob Chemother; 1994 Oct; 34(4):565-77. PubMed ID: 7868408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative in vitro activities of amoxicillin-clavulanate, ampicillin-sulbactam and piperacillin-tazobactam against strains of Escherichia coli and proteus mirabilis harbouring known beta-lactamases.
    Gatermann S; Marre R
    Infection; 1991; 19(2):106-9. PubMed ID: 1646771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro susceptibility of Stenotrophomonas maltophilia to various antimicrobial combinations.
    Krueger TS; Clark EA; Nix DE
    Diagn Microbiol Infect Dis; 2001; 41(1-2):71-8. PubMed ID: 11687317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
    Sader HS; Tosin I; Sejas L; Miranda E
    Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of ticarcillin/clavulanate and piperacillin/tazobactam (YTR 830; CL-298,741) against clinical isolates and against mutants derepressed for class I beta-lactamase.
    Knapp CC; Sierra-Madero J; Washington JA
    Diagn Microbiol Infect Dis; 1989; 12(6):511-5. PubMed ID: 2560423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactions of tazobactam and clavulanate with inducibly- and constitutively-expressed Class I beta-lactamases.
    Akova M; Yang Y; Livermore DM
    J Antimicrob Chemother; 1990 Feb; 25(2):199-208. PubMed ID: 2158496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Susceptibility of Escherichia coli isolates with TEM-1 beta-lactamase to combinations of BRL42715, tazobactam or clavulanate with piperacillin or amoxycillin .
    Livermore DM; Seetulsingh P
    J Antimicrob Chemother; 1991 Jun; 27(6):761-7. PubMed ID: 1669013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of amoxycillin/clavulanate and ticarcillin/clavulanate compared with that of other antibiotics against anaerobic bacteria: comparison with the results of the 1987 survey.
    Pierard D; De Meyer A; Rosseel P; Van Cauwenbergh M; Struelens MJ; Delmee M; Goossens H; Claeys G; Glupczynski Y; Verbist L; Melin P; Lauwers S
    Acta Clin Belg; 1996; 51(2):70-9. PubMed ID: 8693871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Piperacillin/tazobactam and ticarcillin/clavulanic acid against resistant Enterobacteriaceae.
    Kempers J; MacLaren DM
    J Antimicrob Chemother; 1990 Oct; 26(4):598-9. PubMed ID: 2174855
    [No Abstract]   [Full Text] [Related]  

  • 16. Disk diffusion test interpretive criteria and quality control recommendations for testing linezolid (U-100766) and eperezolid (U-100592) with commercially prepared reagents.
    Biedenbach DJ; Jones RN
    J Clin Microbiol; 1997 Dec; 35(12):3198-202. PubMed ID: 9399519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibacterial activity of clavulanate and tazobactam on Peptostreptococcus spp.
    Reig M; Baquero F
    J Antimicrob Chemother; 1994 Feb; 33(2):358-9. PubMed ID: 8182024
    [No Abstract]   [Full Text] [Related]  

  • 18. Susceptibility of clinical isolates to expanded-spectrum beta-lactams alone and in the presence of beta-lactamase inhibitors.
    Qadri SM; Ueno Y; Cunha BA
    Chemotherapy; 1996; 42(5):334-42. PubMed ID: 8874972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections.
    Nomura S; Hanaki H; Nagayama A
    J Chemother; 1997 Apr; 9(2):89-94. PubMed ID: 9176745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beta-lactamase inhibitors and Acinetobacter spp.
    Eng RH; Smith SM; Cherubin CE
    J Antimicrob Chemother; 1990 Sep; 26(3):449-51. PubMed ID: 2172200
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.